Skip to content

UCAN CAN-DU: Canada-Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic Disease

Juvenile Idiopathic Arthritis

Childhood arthritis is a chronic disabling disease. New medications called biologic therapies are now available to treat arthritis that target key biologic molecules that cause inflammation. Biologic therapies, while very effective in treating arthritis in children, may have serious side effects including infections and potentially cancers, and are very expensive and doctors don't know, which one to choose for which child. The investigators will develop tests that enable them to learn about the biology of each child's arthritis and be able to predict when and which biologic therapy to start and when to stop.

null

Participation Requirements

  • Sex:

    ALL
  • Eligible Ages:

    0 to 18

Participation Criteria

Inclusion Criteria:

Cohort 1: - Biologic Basis of JIA

* ≤18 years\*
* Active objective arthritis suspected to be JIA or diagnosed with JIA within 6 months of enrolment
* Treatment naïve except for NSAIDs, allowed to have received NSAIDS within 6 months of diagnosis

Cohort 2 - Start Biologics

* JIA diagnosis as per ILAR criteria (all subtypes)
* ≤18 years\*
* Active arthritis
* For sJIA, active disease not necessarily with arthritis.
* Time of start, restart or switch biologic therapy: e.g. failure, insufficient/partial response or intolerance

Cohort 3 - Stop Biologics

* JIA diagnosis as per ILAR criteria (all subtypes)
* ≤18 years\*
* Inactive disease
* Discontinuing/tapering biologics for inactive disease

Cohort 4: Extreme Phenotypes

* Unexplained systemic inflammation with arthritis/arthralgia as a part of manifestations
* High suspicion of genetic contribution
* Severely affected patients with difficult to control disease (ie failure of multiple biologics)

Exclusion Criteria:

Cohort 1 :

* Arthritis explained by another diagnosis
* Joint injections as previous treatment less than 4 weeks prior to enrollment

Cohort 2:

* Arthritis explained by any other cause
* Start on biologics as an indication for uveitis only

Cohort 3:

- Tapering scheme \> 12 months to complete biologics stop

Cohort 4:

- Arthritis explained by another diagnosis

Study Location

BC Children's Hospital
BC Children's Hospital
Vancouver, British Columbia
Canada

Contact Study Team

Montréal Children's Hospital
Montréal Children's Hospital
Montréal, Quebec
Canada

Contact Study Team

McMaster Children's Hospital
McMaster Children's Hospital
Hamilton, Ontario
Canada

Contact Study Team

Stollery Children's Hospital
Stollery Children's Hospital
Edmonton, Alberta
Canada

Contact Study Team

IWK Health Centre
IWK Health Centre
Halifax, Nova Scotia
Canada

Contact Study Team

The Hospital for Sick Children
The Hospital for Sick Children
Toronto, Ontario
Canada

Contact Study Team

Children's Hospital Health Science Centre Winnipeg
Children's Hospital Health Science Centre Winnipeg
Winnipeg, Manitoba
Canada

Contact Study Team

Children's Hospital, London Health Sciences Centre
Children's Hospital, London Health Sciences Centre
London, Ontario
Canada

Contact Study Team

University of Saskatchewan
University of Saskatchewan
Saskatoon, Saskatchewan
Canada

Contact Study Team

Alberta Children's Hospital - University of Calgary
Alberta Children's Hospital - University of Calgary
Calgary, Alberta
Canada

Contact Study Team

Janeway Children's Hospital and Rehabilitation Centre
Janeway Children's Hospital and Rehabilitation Centre
St John's, Newfoundland and Labrador
Canada

Contact Study Team

Children's Hospital of Eastern Ontario
Children's Hospital of Eastern Ontario
Ottawa, Ontario
Canada

Contact Study Team

Primary Contact

Michele Gibbon

[email protected]
Study Sponsored By
The Hospital for Sick Children
Participants Required
More Information
Study ID: NCT06560606